EP3394103
SAMBLAND AF AND-PD-1 MÓTEFNUM OG TVÍSÉRTÆKUM AND-CD20/ANTI-CD3 MÓTEFNUM TIL MEÐFERÐAR VIÐ KRABBA
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
21.12.2016EP published:
28.6.2023EP application number:
16826557.7
EP translation filed:
24.8.2023Grant published:
15.10.2023EPO information:
European Patent Register
Max expiry date:
20.12.2036Expiry date:
20.12.2026Next due date:
31.12.2026
Title in English:
COMBINATION OF ANTI-PD-1 ANTIBODIES AND BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT CANCERLanguage of the patent:
English
Timeline
Today
21.12.2016EP application
28.6.2023EP Publication
24.8.2023Translation submitted
15.10.2023Registration published
20.12.2026Expires
Owner
Name:
Regeneron Pharmaceuticals, Inc.Address:
777 Old Saw Mill River Road, Tarrytown, NY 10591, US
Inventor
Name:
VARGHESE, BinduAddress:
Tarrytown NY 10591, US
Name:
THURSTON, GavinAddress:
Tarrytown NY 10591, US
Name:
LOWY, IsraelAddress:
Tarrytown NY 10591, US
Name:
BROWNSTEIN, CarrieAddress:
Tarrytown NY 10591, US
Agent
Name:
Tego IP ehf.Address:
Pósthólf 8129, 128, Reykjavík,
Priority
Number:
201562270749 PDate:
22.12.2015Country:
US
Classification
Categories:
A61P 35/02, C07K 16/28, A61P 35/00, A61K 39/00, A61K 45/06, C07K 16/30, A61K 39/395, A61P 43/00
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 12.12.2023
Expires: 20.12.2024
Payer: Árnason Faktor ehf.
Number: 9
Paid: 28.11.2024
Expires: 20.12.2025
Payer: Árnason Faktor ehf.
Number: 10
Paid: 15.12.2025
Expires: 20.12.2026
Payer: Árnason Faktor ehf.